Cargando…

Methods to appraise available evidence and adequacy of data from a systematic literature review to conduct a robust network meta-analysis of treatment options for patients with hospital-acquired or ventilator-associated bacterial pneumonia

We aimed to determine if available evidence from a previously conducted systematic literature review was sufficient to conduct a robust network meta-analysis (NMA) using the International Society for Pharmacoeconomics and Outcomes Research Good Practice Task Force NMA study questionnaire to evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Puzniak, Laura, Dillon, Ryan, Lodise, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812328/ https://www.ncbi.nlm.nih.gov/pubmed/36598902 http://dx.doi.org/10.1371/journal.pone.0279844

Ejemplares similares

Cost Effectiveness of Ceftolozane/Tazobactam Compared with Meropenem for the Treatment of Patients with Ventilated Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
por: Naik, Jaesh, et al.
Publicado: (2021)

Healthcare Resource Utilization of Ceftolozane/Tazobactam Versus Meropenem for Ventilated Nosocomial Pneumonia from the Randomized, Controlled, Double-Blind ASPECT-NP Trial
por: Lodise, Thomas, et al.
Publicado: (2020)

The risk of inappropriate empiric treatment and its outcomes based on pathogens in non-ventilated (nvHABP), ventilated (vHABP) hospital-acquired and ventilator-associated (VABP) bacterial pneumonia in the US, 2012–2019
por: Zilberberg, Marya D., et al.
Publicado: (2022)

Descriptive Epidemiology and Outcomes of Nonventilated Hospital-Acquired, Ventilated Hospital-Acquired, and Ventilator-Associated Bacterial Pneumonia in the United States, 2012–2019
por: Zilberberg, Marya D., et al.
Publicado: (2021)

Cost–effectiveness of imipenem/cilastatin/relebactam for hospital-acquired and ventilator-associated bacterial pneumonia
por: Naik, Jaesh, et al.
Publicado: (2023)

Impact of the adequacy of antibiotic therapy on the outcome of ventilator-associated pneumonia
por: Goncalves-Pereira, J, et al.
Publicado: (2011)

Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections
por: Goodman, Julian J, et al.
Publicado: (2012)

2200. Cost-effectiveness of Ceftolozane/Tazobactam for Treating Ventilated Nosocomial Bacterial Pneumonia
por: Naik, Jaesh, et al.
Publicado: (2019)

Pain management following spinal surgeries: An appraisal of the available options
por: Bajwa, Sukhminder Jit Singh, et al.
Publicado: (2015)

1462. Hospital Admission Patterns in Adult Patients with Community-Acquired Bacterial Pneumonia Who Received Ceftriaxone and a Macrolide by Pneumonia Severity Index Score
por: Lodise, Thomas, et al.
Publicado: (2018)

Cefiderocol as a Treatment Option for Stenotrophomonas maltophilia Causing Hospital-Acquired/Ventilator-Associated Pneumonia
por: Rashid, Muhammad Humayoun, et al.
Publicado: (2023)

Use of Oral Tetracyclines in the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia: A Literature Review on the Often-Overlooked Antibiotic Class
por: Bidell, Monique R., et al.
Publicado: (2020)

The Role of Delafloxacin in Patients with Community-Acquired Bacterial Pneumonia in the Outpatient Setting: A Budget Impact Model
por: Lodise, Thomas P., et al.
Publicado: (2020)

2270. Initial Treatment Selection Among Patients with Recurrent Pseudomonas aeruginosa (PSA) Infections (Infxs): Does Prior PSA Antibiotic Susceptibility Results Effect Subsequent Empiric Treatment Decisions?
por: Puzniak, Laura, et al.
Publicado: (2019)

Determinants of Mortality for Ventilated Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia
por: Motowski, Hayley, et al.
Publicado: (2023)

Cost Drivers of a Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Phase 3 Clinical Trial
por: Stergiopoulos, Stella, et al.
Publicado: (2018)

Bench-to-bedside review: Therapeutic options and issues in the management of ventilator-associated bacterial pneumonia
por: Rello, Jordi
Publicado: (2005)

Decision Analysis: Omadacycline Relative to Moxifloxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difficile Infection
por: Lodise, Thomas P., et al.
Publicado: (2021)

Ceftriaxone resistance and adequacy of initial antibiotic therapy in community onset bacterial pneumonia
por: Van Besien, Richard F., et al.
Publicado: (2022)

Ceftaroline Fosamil for the Treatment of Community-Acquired Pneumonia: from FOCUS to CAPTURE
por: Carreno, Joseph J., et al.
Publicado: (2014)

Correction to: Decision Analysis: Omadacycline Relative to Moxifoxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difcile Infection
por: Lodise, Thomas P., et al.
Publicado: (2021)

The Availability and Nutritional Adequacy of Gluten-Free Bread and Pasta
por: Allen, Beatrice, et al.
Publicado: (2018)

Is ventilated hospital-acquired pneumonia a worse entity than ventilator-associated pneumonia?
por: Vallecoccia, Maria Sole, et al.
Publicado: (2020)

Deep Learning-Based Available and Common Clinical-Related Feature Variables Robustly Predict Survival in Community-Acquired Pneumonia
por: Feng, Ding-Yun, et al.
Publicado: (2021)

2599. Impact of Alveolar Neutrophilia on Outcomes in Patients with Suspected Ventilated Hospital-Acquired Bacterial Pneumonia
por: Saravolatz, Louis, et al.
Publicado: (2023)

Community-Acquired Pneumonia, Bacterial
por: File, Thomas M.
Publicado: (2012)

1623. Outcomes of Critically Ill Adults, Hospitalized Patients (Pts) with Pseudomonas aeruginosa (PSA) Hospital- and Ventilator-Associated Pneumonia (HAP/VAP) Who Received an Active Anti-Pseudomonal β-Lactam (ASPB): Does “S” Equal Success in the Presence of Resistance to other ASPB?
por: Lodise, Thomas, et al.
Publicado: (2020)

Prevention of Community-Acquired Pneumonia with Available Pneumococcal Vaccines
por: Principi, Nicola, et al.
Publicado: (2016)

EE388 Cost Effectiveness of Novel Antibiotic Ceftolozane/Tazobactam in Patients With Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia in Greece
por: Yfantopoulos, N, et al.
Publicado: (2022)

1463. Comparative Evaluation of Adverse Tendon Events Between Recipients of Fluoroquinolones and Ceftriaxone/Azithromycin Among Veterans Affairs Patients with Community Acquired Bacterial Pneumonia
por: Patel, Nimish, et al.
Publicado: (2018)

Aerosolized antibiotics in the treatment of hospital-acquired pneumonia/ventilator-associated pneumonia
por: Jung, Yun Jung, et al.
Publicado: (2022)

What is new in non-ventilated ICU-acquired pneumonia?
por: Saied, Wafa Ibn, et al.
Publicado: (2020)

Viruses are prevalent in non-ventilated hospital-acquired pneumonia
por: Shorr, Andrew F., et al.
Publicado: (2017)

Summary of the international clinical guidelines for the management of hospital-acquired and ventilator-acquired pneumonia
por: Torres, Antoni, et al.
Publicado: (2018)

Implementation of a ventilator care bundle to reduce the incidence of ventilator acquired pneumonia
por: Mandal, AK, et al.
Publicado: (2011)

Adequacy of oxygenation parameters in elderly patients undergoing mechanical ventilation
por: Guedes, Luana Petruccio Cabral Monteiro, et al.
Publicado: (2013)

Nutritional Adequacy in Mechanically Ventilated Patient: Are We Doing Enough?
por: Kalaiselvan, MS, et al.
Publicado: (2021)

Appraisal of clinical practice guidelines on community-acquired pneumonia in children with AGREE II instrument
por: Xie, Zhenwei, et al.
Publicado: (2016)

Performance and impact of a multiplex PCR in ICU patients with ventilator-associated pneumonia or ventilated hospital-acquired pneumonia
por: Peiffer-Smadja, Nathan, et al.
Publicado: (2020)

Adequacy of evidence available to support the claims of efficacy of Ayurvedic medicines and treatments
por: Manohar, P. Ram
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_i2f7lupq752infqrmhmadv11kc